Şunu aradınız:: magunguna (Hausa - İngilizce)

shin akwai wasu magunguna suna rage lokacin da aka kwantar da majinyata asibiti?
do any of the drugs reduce the time a patient is hospitalized?

hakanan zamu iya bibiyar tasiri ko kowane mummunan sakamako game da waɗannan magunguna ko sinadarai.
we could also follow up on the effectiveness or any adverse reactions to these medicines or vaccinations.

har yanzu an yarda da jigilar kayayyaki masu mahimmanci, magunguna, man fetur da kayan abinci.
transport of essential goods -- medical, fuel and food -- was still allowed.

bincike a kan hanyoyin jiyya ta fara a janairu 2020, kuma ana kan gwajin magunguna na yaki da cututtuka da dama.
research into potential treatments started in january 2020, and several antiviral drugs are in clinical trials.

b0at1 na iya zama makasudin warkewa don gwajin magunguna don murƙushe kamuwa da cutar sars-cov-2.
b0at1 may become a therapeutic target for drug screening to suppress sars-cov-2 infection.

aiki ne da wajibin ci gaban magunguna don tantance duk waɗannan sigogi kafin gwajin asibiti na ɗan adam don tabbatar da amincin da kuma inganci.
it is the function and obligation of drug development to assess all of these parameters prior to human clinical trials to prove safety and efficacy.

a ranar 18 ga watan maris who ta sanar cewa choloroquine da dangin hydroxychloroqueen na daga ciki magunguna hudu wanda za a yi gwajin kiwon lafiya dasu na hadin kai.
on 18 march, the who announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the solidarity clinical trial.

a canada a ranar 16 ga watan afrilu 2020, makarantar magunguna karkashin jamiar waterloo sun sanar da feshin hanci a matsayin maganin su na kwayar halittar dna.
in canada on 16 april 2020, the university of waterloo school of pharmacy announced design of a dna-based vaccine candidate as a possible nasal spray.

babu tabbatacciyar magani dake yakar kwayar cutar covid-19 amma har yanzu ana yunkurin ganowa cikin yunkurin da ake akwai gwajin magunguna da aka riga aka sarrafa.
there are no specific antiviral medications approved for covid-19, but development efforts are underway, including testing of existing medications.

a farkon maganin alurar rigakafi ko haɓaka magunguna, ba a san ƙarami game da aminci, yawan guba, pharmacokinetics, da metabolism na nce a cikin mutane.
at the beginning of vaccine or drug development, little is known about the safety, toxicity, pharmacokinetics, and metabolism of the nce in humans.

wani rahoton cepi na masu fasaha a watan afrilu, magunguna 115 aka fara kerowa da 78 tabbatatu masu cigaba 79 a cewar makarantar miken 37 son sanar amman babu bayani a cikin alumma ana zaton suna tsari ko shiryawa a dakunan gwaji da dama.
as reported by cepi scientists in april, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the milken institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).

kula da akalla samar da magunguna na kwanaki 30, wadatar abinci na sati 2 da sauran buƙatu, da kuma sanin alamun covid-19 ana bada shawarar ga waɗanda ke da yanayin rashin lafiyar.
maintaining at least a 30-day supply of medication, a 2-week supply of food and other necessities, and knowledge of covid-19 symptoms are recommended for those with underlying health conditions.

hussein aa, da ma wasu sun karanci kowani kwayar halitar sannan suka auna tare da gwada kamanceceniyar kwarangwal da magunguna wanda suka fi karbuwa don gaggauta samar da maganin sars cov-2 a yayin gwajin kiwon lafiya dln shawarta a tsarin binciken kiwon lafiya.
hussein a a, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-sars-cov-2 drug development in his preclinical study to be recommended in a clinical study design.

dangane da takardun bincike da aka buga a 2005 da 2006, ganowa da haɓaka allurar rigakafi da magunguna don magance sars ya kasance fifiko ga gwamnatoci da hukumomin kiwon lafiyar jama’a duniya. hakanan babu wani ingantaccen maganin alurar rigakafi kan mers.
according to research papers published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat sars was a priority for governments and public health agencies around the world.there is also no proven vaccine against mers.

an kafa tsarin kwalliya, tsari mai zurfi a cikin afrilu 2020 don bin diddigin ci gaban gwajin asibiti don rajistar maganin covid-19 da kuma 'yan takarar maganin warkewa. alurar rigakafi da haɓaka magunguna tsari ne da yawa, galibi yana buƙatar fiye da shekaru biyar don tabbatar da lafiya da kuma ingancin sabon mahadi.
a dynamic, systematic review was established in april 2020 to track the progress of registered clinical trials for covid-19 vaccine and therapeutic drug candidates.vaccine and drug development is a multistep process, typically requiring more than five years to assure safety and efficacy of the new compound.